Open AccessEffect of Add‐on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease
Author(s) -
Ozeki Atsuko,
Amiya Eisuke,
Watanabe Masafumi,
Hosoya Yumiko,
Takata Munenori,
Watanabe Aya,
Kawarasaki Shuichi,
Nakao Tomoko,
Watanabe Shogo,
Omori Kazuko,
Yamada Namie,
Tahara Yukiko,
Hirata Yasunobu,
Nagai Ryozo
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12366
Subject(s) - aliskiren , medicine , valsartan , cardiology , vasodilation , heart rate , endothelial dysfunction , renin–angiotensin system , blood pressure
The aim of this study was to evaluate the add‐on effect of aliskiren to valsartan on endothelial‐dependent vasodilation in hypertensive patients with ischemic heart disease ( IHD ). After 4 weeks of treatment with 80 mg of valsartan, 28 patients were allocated to either continued treatment with valsartan or an add‐on treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly decreased plasma renin activity, whereas endothelium‐dependent vasodilation measured by flow‐mediated dilation ( FMD ) did not change. In contrast, heart rate significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline and 24 weeks, respectively [P = .009]) and the standard deviation of the R‐R intervals ( SDNN ) significantly increased in the aliskiren group. The add‐on aliskiren to valsartan therapy may not improve endothelial functions, although it significantly reduced resting heart rate via regulation of the autonomic nervous system in hypertensive patients with IHD .